Cybin (CYBN) News Today → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free CYBN Stock Alerts $0.43 0.00 (0.00%) (As of 03/27/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC Filings All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadline3 Penny Stocks That Could Be Multibaggers in the Making: March Editioninvestorplace.com - March 26 at 2:19 PMCybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Millionbusinesswire.com - March 19 at 11:53 AMCybin to Present at Public Ventures Discovery Day on March 19th in Dallasbusinesswire.com - March 18 at 7:30 AMCybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorderbusinesswire.com - March 15 at 7:30 AMCybin’s CYB003 Shows Promise in MDD Treatment, Justifying Buy Ratingmarkets.businessinsider.com - March 14 at 6:22 PMCybin to begin Phase 3 study for psychedelic drug mid-yearmsn.com - March 14 at 1:21 PMBuy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA Designationsmarkets.businessinsider.com - March 14 at 8:20 AMCybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Designbusinesswire.com - March 14 at 7:30 AMCybin Gets Breakthrough Therapy Designation For Its Psychedelic-based Therapeutic CYB003markets.businessinsider.com - March 13 at 7:03 AMCybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorderbusinesswire.com - March 13 at 6:00 AMCybin to Host Conference Call and Webcast to Provide Program Update for CYB003businesswire.com - March 12 at 10:37 PM3 High-Potential Penny Stocks to Turn $1000 into $1 millioninvestorplace.com - March 10 at 5:00 PMCybin to Present at the TD Cowen 44th Annual Health Care Conferencebusinesswire.com - February 27 at 7:30 AMCybin Inc.thestreet.com - February 16 at 8:39 AMCybin Reports Third Quarter Financial Results and Recent Business Highlightsfinance.yahoo.com - February 14 at 8:46 AMCybin Reports Third Quarter Financial Results and Recent Business Highlightsbusinesswire.com - February 14 at 7:45 AMCybin (OTCMKTS:CYBN) Trading Up 10.8%marketbeat.com - February 13 at 3:02 AMCybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Programfinance.yahoo.com - February 7 at 7:51 AMFDA Green Lights Cybin's Psychedelic Clinical Study Assessing Generalized Anxietymsn.com - January 23 at 2:24 PMCybin gets FDA clearance for Phase 2a study of psychedelic drugmsn.com - January 23 at 2:24 PMCybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorderfinance.yahoo.com - January 23 at 8:57 AMBuy Rating Affirmed for Cybin Based on Advancements in Psychedelic Treatments and Optimistic Valuationmarkets.businessinsider.com - January 5 at 7:57 AMCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Programfinance.yahoo.com - December 6 at 9:57 AMCybin Reports Positive Data From Phase 2 CYB003 In Major Depressive Disordermarkets.businessinsider.com - November 30 at 8:28 AMCybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Dosesfinance.yahoo.com - November 30 at 8:28 AMCybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York Cityfinance.yahoo.com - November 20 at 9:28 AMCybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goalsmsn.com - November 15 at 4:58 PMThinking about buying stock in Tesla Inc, Chevron, Theseus Pharmaceuticals, Cybin Inc, or NXU Inc.?benzinga.com - November 15 at 11:58 AMCybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Dealbenzinga.com - November 10 at 3:40 PMCybin Prices Offering Of About 66.67 Mln Units At $0.45/unitmarkets.businessinsider.com - November 10 at 10:39 AMCybin Inc Ordinary Sharesmorningstar.com - November 8 at 9:00 PMSmall Pharma Obtains Final Order Approving Arrangementfinance.yahoo.com - October 17 at 6:20 PMPsyched: Steve Cohen's New Biopharma Bet, California Gov. Authorizes Medical Psychedelics & Morebenzinga.com - October 6 at 6:32 PMCybin to Present at the Jefferies Inaugural Biotech CNS/Neuro Summitfinance.yahoo.com - October 4 at 8:41 AMCybin Completes Dosing in Phase 2 Study of CYB003 for the Treatment of Major Depressive Disorderfinance.yahoo.com - October 3 at 9:18 AMCybin’s Promising Developments and Emerging Data: A Comprehensive Analysis Justifying Buy Rating and $10 Price Targetmarkets.businessinsider.com - October 2 at 1:15 PMCybin to Participate in the Cantor Global Healthcare Conferencefinance.yahoo.com - September 25 at 9:39 AMWall Street Hedge Fund Genius Bets on Cybin Inc.finanznachrichten.de - September 20 at 11:45 PMCybin shares continue to rise on major investment from Steve Cohen's hedge fundproactiveinvestors.com - September 20 at 1:44 PMCybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMTbenzinga.com - September 5 at 5:11 PMCybin Announces Grant of U.S. Patent Covering Deuterated Tryptaminesfinance.yahoo.com - September 5 at 5:11 PMWhat 11 Analyst Ratings Have To Say About Cybinmarkets.businessinsider.com - September 1 at 4:19 PMCybin Buying Small Pharma in All-Stock Transactionmarketwatch.com - August 29 at 6:53 PMCybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxietybenzinga.com - August 28 at 4:04 PMCybin stock falls on pricing discounted stock and warrants offeringmsn.com - August 3 at 9:44 AMCybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorderfinance.yahoo.com - August 2 at 11:59 AMCybin Announces Overnight Marketed Public Offering of Unitsfinance.yahoo.com - July 31 at 7:18 PMCybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brainfinance.yahoo.com - July 20 at 5:47 PMEMulate Therapeutics Announces Brett Greene, Veteran in the Psychedelic and Cannabinoid Biotechnology Industry, as a Company Advisorfinance.yahoo.com - July 18 at 8:41 AMCybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCTfinance.yahoo.com - July 12 at 10:08 AM Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address The Small Biotech with a BIG Cancer Solution (Ad)There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells. Get the full story here >>> CYBN Media Mentions By Week CYBN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYBN News Sentiment▼1.000.63▲Average Medical News Sentiment CYBN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYBN Articles This Week▼11▲CYBN Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Theseus Pharmaceuticals News Today CorMedix News Today NervGen Pharma News Today Verastem News Today MediciNova News Today Nautilus Biotechnology News Today Harpoon Therapeutics News Today Arbutus Biopharma News Today Global Cord Blood News Today Inventiva News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:CYBN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.